E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced or Metastatic Liposarcoma or Leiomyosarcoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 5.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10039494 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare time to progression of 2 administration schedules in subjects with liposarcoma and leiomyosarcoma previously treated with anthracycline and ifosfamide. |
|
E.2.2 | Secondary objectives of the trial |
for each treatment arm are as follows: ·to estimate the rate and duration of best overall objective responses (CR+PR) ·to compare the overall survival (OS), and ·to characterize the safety profile ·to estimate the pharmacokinetics of YONDELIS i.v. formulation
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1.Signed informed consent. 2.Male or female subjects 18 years-of-age or older. 3.Unresectable advanced or metastatic histologically proven liposarcoma or leiomyosarcoma. Subjects with GIST (gastrointestinal stromal tumors) are not eligible. 4.Subjects must have pathology specimens available for centralized review. 5.Subjects must have relapsed or progressive disease prior to enrollment. Subjects must have been treated with an anthracycline and ifosfamide, administered either in combination or as sequential regimens. 6.Progressive, measurable disease as defined in the RECIST guidelines. If the only indicator lesion is in a previously irradiated area, the recurrence must be biopsy proven. 7.Recovery from toxic effects of prior therapies to National Cancer Institute-Common Toxicity Criteria (NCI CTC) Grade 1 or better. 8.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 9.Hematologic variables: -Hemoglobin ≥9 g/dL -Absolute neutrophil count (ANC) ≥1,500/mL -Platelet count ≥100,000/mL
10.Serum creatinine £ upper limit of normal (ULN) 11.Hepatic function variables -Total bilirubin ≤ULN -Total alkaline phosphatase ≤ ULN, or if > ULN, then alkaline phosphatase liver fraction or 5’-nucleotidase must be ≤ ULN. -AST (serum aspartate transaminase [SGOT]) and ALT (serum alanine transaminase [SGPT]) must be ≤2.5xULN -Albumin ≥2.5 g/dL
|
|
E.4 | Principal exclusion criteria |
1.Pregnant or breast–feeding women, or subjects (male or female) not employing adequate contraception. Acceptable means of birth control include intrauterine device (IUD), oral contraceptive, subdermal implant, and a condom with a contraceptive sponge or suppository. 2.Prior exposure to YONDELIS i.v. formulation, ET-743 (ecteinascidin). 3.More than 2 prior cytotoxic chemotherapy regimens (adjuvant therapy completed more than 18 months before randomization will not be counted as a regimen). 4.Less than 4 weeks from last dose of systemic cytotoxic therapy, radiation therapy, or therapy with any investigational agent. 5.Peripheral neuropathy, Grade 2 or higher. 6.History of another neoplastic disease (except basal cell carcinoma or cervical carcinoma in situ adequately treated), unless in remission 5 years or more. 7.Known central nervous system (CNS) metastasis. 8.Active viral hepatitis or chronic liver disease. 9.Unstable cardiac condition, including congestive heart failure or angina pectoris, myocardial infarction within 1 year before enrollment, uncontrolled arterial hypertension or arrhythmias. 10.Active infection |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint of the study will be Time-to-progression (TTP). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
parallel group with optional cross-over |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |